[DOTA]Somatostatin-14 analogs and their In-111-radioligands: Effects of decreasing ring-size on sst(1-5) profile, stability and tumor targeting

A Tatsi, T Maina, R Cescato, B Waser, Eric Krenning, P Cordopatis, Marion Jong, JC (Jeanclaude) Reubi, Berthold Nock

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)

Abstract

Multiple somatostatin receptor (sst)-subtype expression has been manifested in several human tumors. Hence, the availability of radiopeptides retaining the full pansomatostatin profile of the native hormone (SS14) is expected to increase the sensitivity and broaden the clinical indications of currently applied sst2-preferring cyclic octapeptide radioligands, like OctreoScan (R) ([In-111-DTPA]octreotide). On the other hand, SS14 has been excluded from clinical use due to its rapid in vivo degradation. We herein present a small library of seven novel cyclic SS14-mimics carrying at their N-terminus the universal chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) for stable binding of medically useful radiometals, like In-111. By decreasing the number of amino acids composing the ring in their structure from 12 up to 6 AA, we induced important changes in key-biological parameters in vitro and in vivo. In particular, we observed unexpected changes and even total loss of sst(1-5)-affinity (6AA-ring), as well as weaker sst(2)-internalization efficacy as the ring size decreased. In contrast, in vivo stability increased with decreasing ring size, reaching its maximum in the 6AA-ring analogs. Interestingly, only the 12AA- and 9AA-ring members of this series showed sst(2)-specific uptake in AR4-2J tumors in mice revealing the prominent role of ring size on the biological response of tested SS14-derived radioligands. (C) 2013 Elsevier Masson SAS. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)30-37
Number of pages8
JournalEuropean Journal of Medicinal Chemistry
Volume73
DOIs
Publication statusPublished - 2014

Cite this